Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACTUNASDAQ:BTMDNASDAQ:CRDFNASDAQ:DTIL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$11.36+7.5%$8.88$5.51▼$11.99$222.88MN/A49,016 shs276,732 shsBTMDbiote$3.49-3.1%$3.56$3.04▼$8.44$189.30M1.17192,782 shs134,984 shsCRDFCardiff Oncology$3.34$2.87$2.01▼$5.64$222.20M1.811.14 million shs906,520 shsDTILPrecision BioSciences$4.86-1.2%$4.93$3.61▼$13.27$53.89M1.55184,655 shs27,941 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics0.00%+9.97%+19.58%+56.91%+1,135,999,900.00%BTMDbiote0.00%-5.16%+6.73%-20.14%-48.07%CRDFCardiff Oncology0.00%+10.23%+23.25%-21.23%+4.37%DTILPrecision BioSciences0.00%+6.11%-15.03%-9.83%-60.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACTUActuate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABTMDbiote3.9559 of 5 stars3.55.00.00.03.33.31.3CRDFCardiff Oncology1.7413 of 5 stars3.50.00.00.04.20.00.6DTILPrecision BioSciences3.7596 of 5 stars3.52.00.04.61.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACTUActuate Therapeutics 3.00Buy$20.5080.46% UpsideBTMDbiote 3.00Buy$8.00129.23% UpsideCRDFCardiff Oncology 3.00Buy$12.00259.28% UpsideDTILPrecision BioSciences 3.00Buy$47.00867.08% UpsideCurrent Analyst Ratings BreakdownLatest DTIL, ACTU, CRDF, and BTMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025DTILPrecision BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.005/9/2025CRDFCardiff OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.004/22/2025ACTUActuate TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.003/28/2025DTILPrecision BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.003/19/2025DTILPrecision BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.003/17/2025ACTUActuate TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.003/13/2025BTMDbioteCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $8.00(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACTUActuate TherapeuticsN/AN/AN/AN/AN/AN/ABTMDbiote$199.38M0.96$0.36 per share9.60($0.58) per share-6.02CRDFCardiff Oncology$587K378.53N/AN/A$1.56 per share2.14DTILPrecision BioSciences$51.14M1.05N/AN/A$4.53 per share1.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACTUActuate Therapeutics-$24.75MN/A0.00∞N/AN/AN/AN/AN/ABTMDbiote$3.32M$0.6113.426.46N/A5.20%-32.41%22.26%8/14/2025 (Estimated)CRDFCardiff Oncology-$41.44M-$0.92N/AN/AN/A-6,238.17%-73.97%-60.40%8/14/2025 (Estimated)DTILPrecision BioSciences-$61.32M-$2.0181.01N/AN/A11.48%-23.69%-6.98%7/30/2025 (Estimated)Latest DTIL, ACTU, CRDF, and BTMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ACTUActuate Therapeutics-$0.26-$0.32-$0.06-$0.32N/AN/A5/15/2025Q1 2025DTILPrecision BioSciences-$0.43-$2.21-$1.78-$2.21$5.00 million$0.03 million5/8/2025Q1 2025CRDFCardiff Oncology-$0.19-$0.20-$0.01-$0.20$0.09 million$0.11 million5/7/2025Q1 2025BTMDbiote$0.06$0.08+$0.02$0.37$47.25 million$48.99 million3/26/2025Q4 2024DTILPrecision BioSciences-$2.09-$3.20-$1.11-$2.22$4.28 million$3.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACTUActuate TherapeuticsN/AN/AN/AN/AN/ABTMDbioteN/AN/AN/AN/AN/ACRDFCardiff OncologyN/AN/AN/AN/AN/ADTILPrecision BioSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACTUActuate TherapeuticsN/A1.681.68BTMDbioteN/A1.501.16CRDFCardiff OncologyN/A4.744.74DTILPrecision BioSciences0.349.229.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACTUActuate TherapeuticsN/ABTMDbiote21.68%CRDFCardiff Oncology16.29%DTILPrecision BioSciences37.99%Insider OwnershipCompanyInsider OwnershipACTUActuate Therapeutics69.34%BTMDbiote24.00%CRDFCardiff Oncology7.70%DTILPrecision BioSciences4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACTUActuate Therapeutics1019.62 millionN/AN/ABTMDbiote19454.71 million46.78 millionNot OptionableCRDFCardiff Oncology2066.53 million47.15 millionOptionableDTILPrecision BioSciences20011.09 million7.36 millionNo DataDTIL, ACTU, CRDF, and BTMD HeadlinesRecent News About These CompaniesQ2 EPS Estimate for Precision BioSciences Cut by AnalystMay 25, 2025 | americanbankingnews.comPrecision BioSciences (NASDAQ:DTIL) Earns Buy Rating from HC WainwrightMay 24, 2025 | americanbankingnews.comPrecision BioSciences' (DTIL) "Buy" Rating Reiterated at HC WainwrightMay 23, 2025 | marketbeat.comUncovering Potential: Precision BioSciences's Earnings PreviewMay 16, 2025 | benzinga.comPrecision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2025 | zacks.comPrecision BioSciences Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | businesswire.comPrecision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual MeetingMay 14, 2025 | businesswire.comPrecision BioSciences Q1 2025 Earnings PreviewMay 14, 2025 | msn.comPrecision BioSciences, Inc. (NASDAQ:DTIL) Shares Sold by Alyeska Investment Group L.P.May 9, 2025 | marketbeat.comPrecision BioSciences to Report First Quarter 2025 Results on May 15, 2025May 8, 2025 | businesswire.comPrecision BioSciences (DTIL) to Release Earnings on MondayMay 7, 2025 | marketbeat.comPrecision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)May 7, 2025 | businesswire.comPrecision BioSciences (DTIL) Receives a Buy from H.C. WainwrightMay 3, 2025 | theglobeandmail.comPrecision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual MeetingMay 1, 2025 | businesswire.comDTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock UpApril 16, 2025 | zacks.comPrecision Medicine Group Appoints Chief Information and Technology OfficerApril 16, 2025 | contractpharma.comPrecision BioSciences stock rises following FDA Fast Track designationApril 15, 2025 | in.investing.comPrecision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis BApril 15, 2025 | businesswire.comPrecision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare ConferenceApril 1, 2025 | businesswire.comInsider Buying: Precision BioSciences, Inc. (NASDAQ:DTIL) Director Buys 3,250 Shares of StockMarch 28, 2025 | insidertrades.comPrecision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue EstimatesMarch 26, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookNVIDIA’s NVLink Fusion Ups the Ante for AI InfrastructureBy Thomas Hughes | May 19, 2025View NVIDIA’s NVLink Fusion Ups the Ante for AI InfrastructureToyota Supercharges Joby: $250M Capital Infusion Ignites Stock By Jeffrey Neal Johnson | May 28, 2025View Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Rockwell Automation: Tailwinds From Onshoring U.S. ProductionBy Thomas Hughes | May 8, 2025View Rockwell Automation: Tailwinds From Onshoring U.S. ProductionCan Shopify Stock Make a Comeback After an Earnings Sell-Off?By Gabriel Osorio-Mazilli | May 12, 2025View Can Shopify Stock Make a Comeback After an Earnings Sell-Off?DTIL, ACTU, CRDF, and BTMD Company DescriptionsActuate Therapeutics NASDAQ:ACTU$11.36 +0.79 (+7.47%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$11.88 +0.52 (+4.58%) As of 05/30/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.biote NASDAQ:BTMD$3.49 -0.11 (-3.06%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$3.62 +0.13 (+3.72%) As of 05/30/2025 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Cardiff Oncology NASDAQ:CRDF$3.34 0.00 (0.00%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$3.48 +0.14 (+4.04%) As of 05/30/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Precision BioSciences NASDAQ:DTIL$4.86 -0.06 (-1.22%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$4.82 -0.04 (-0.82%) As of 05/30/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
